JP2024515650A5 - - Google Patents
Info
- Publication number
- JP2024515650A5 JP2024515650A5 JP2023563210A JP2023563210A JP2024515650A5 JP 2024515650 A5 JP2024515650 A5 JP 2024515650A5 JP 2023563210 A JP2023563210 A JP 2023563210A JP 2023563210 A JP2023563210 A JP 2023563210A JP 2024515650 A5 JP2024515650 A5 JP 2024515650A5
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- composition according
- mol
- lnp composition
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163176227P | 2021-04-17 | 2021-04-17 | |
| US63/176,227 | 2021-04-17 | ||
| US202163254948P | 2021-10-12 | 2021-10-12 | |
| US63/254,948 | 2021-10-12 | ||
| US202163274153P | 2021-11-01 | 2021-11-01 | |
| US63/274,153 | 2021-11-01 | ||
| US202263316568P | 2022-03-04 | 2022-03-04 | |
| US63/316,568 | 2022-03-04 | ||
| PCT/US2022/025076 WO2022221697A1 (en) | 2021-04-17 | 2022-04-15 | Lipid nanoparticle compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024515650A JP2024515650A (ja) | 2024-04-10 |
| JP2024515650A5 true JP2024515650A5 (cg-RX-API-DMAC7.html) | 2025-04-21 |
Family
ID=81580499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023563210A Pending JP2024515650A (ja) | 2021-04-17 | 2022-04-15 | 脂質ナノ粒子組成物 |
Country Status (14)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7883580B2 (ja) * | 2021-10-08 | 2026-07-01 | スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド | 脂質化合物及び脂質ナノ粒子組成物 |
| EP4638783A2 (en) | 2022-12-22 | 2025-10-29 | Intellia Therapeutics, Inc. | Methods for analyzing nucleic acid cargos of lipid nucleic acid assemblies |
| WO2024199282A1 (zh) * | 2023-03-28 | 2024-10-03 | 苏州艾博生物科技有限公司 | 脂质化合物和脂质纳米颗粒组合物 |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025049481A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods of editing an hla-a gene in vitro |
| WO2025049432A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods for editing hla-a in cells pre-screened for the absence of one or both alleles of hla-h*01 |
| EP4780984A1 (en) | 2023-09-18 | 2026-07-29 | Intellia Therapeutics, Inc. | Nuclease resistant single stranded dna product for non-viral delivery to a cell and methods of production thereof |
| EP4780983A1 (en) | 2023-09-18 | 2026-07-29 | Intellia Therapeutics, Inc. | Nuclease resistant double stranded dna product for non-viral delivery to a cell and methods of production thereof |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025137301A1 (en) * | 2023-12-20 | 2025-06-26 | Intellia Therapeutics, Inc. | Methods for rapid engineering of cells |
| WO2025240946A1 (en) | 2024-05-17 | 2025-11-20 | Intellia Therapeutics, Inc. | Lipid nanoparticles and lipid nanoparticle compositions |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1021549A2 (en) | 1997-09-19 | 2000-07-26 | Sequitur, Inc. | SENSE mRNA THERAPY |
| WO2006007712A1 (en) | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
| WO2011076807A2 (en) | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| EP2526199A4 (en) | 2010-01-22 | 2013-08-07 | Scripps Research Inst | PROCESS FOR PRODUCING ZINC FINGERUCLEASES WITH CHANGED EFFECT |
| CN103668470B (zh) | 2012-09-12 | 2015-07-29 | 上海斯丹赛生物技术有限公司 | 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法 |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| PT2931898E (pt) | 2012-12-12 | 2016-06-16 | Harvard College | Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais |
| IL308158A (en) | 2012-12-17 | 2023-12-01 | Harvard College | Rna-guided human genome engineering |
| ES2887254T3 (es) | 2013-03-08 | 2021-12-22 | Novartis Ag | Lípidos y composiciones lipídicas para el suministro de agentes activos |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| US10059655B2 (en) | 2013-12-19 | 2018-08-28 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| HRP20220156T1 (hr) | 2015-09-17 | 2022-04-15 | Modernatx, Inc. | Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| WO2019147805A2 (en) | 2018-01-26 | 2019-08-01 | The Board Of Trustees Of The Leland Stanford Junior University | Regulatory t cells targeted with chimeric antigen receptors |
| MX2021011690A (es) * | 2019-03-28 | 2022-01-06 | Intellia Therapeutics Inc | Composiciones y métodos para la edición del gen ttr y el tratamiento de la amiloidosis attr que comprende un corticosteroide o uso de este. |
| WO2020219876A1 (en) | 2019-04-25 | 2020-10-29 | Intellia Therapeutics, Inc. | Ionizable amine lipids and lipid nanoparticles |
| JP7600208B2 (ja) * | 2019-07-29 | 2024-12-16 | ジョージア テック リサーチ コーポレイション | 拘束された脂質を含むナノ材料およびその使用 |
-
2022
- 2022-04-15 EP EP22721589.4A patent/EP4322920A1/en active Pending
- 2022-04-15 IL IL307738A patent/IL307738A/en unknown
- 2022-04-15 BR BR112023021477A patent/BR112023021477A2/pt not_active Application Discontinuation
- 2022-04-15 US US18/287,239 patent/US20250090471A1/en active Pending
- 2022-04-15 AU AU2022257050A patent/AU2022257050A1/en active Pending
- 2022-04-15 WO PCT/US2022/025076 patent/WO2022221697A1/en not_active Ceased
- 2022-04-15 TW TW111114501A patent/TW202308597A/zh unknown
- 2022-04-15 MX MX2023012235A patent/MX2023012235A/es unknown
- 2022-04-15 CR CR20230536A patent/CR20230536A/es unknown
- 2022-04-15 CA CA3216877A patent/CA3216877A1/en active Pending
- 2022-04-15 JP JP2023563210A patent/JP2024515650A/ja active Pending
- 2022-04-15 KR KR1020237039429A patent/KR20240017792A/ko active Pending
-
2023
- 2023-10-16 CL CL2023003077A patent/CL2023003077A1/es unknown
- 2023-11-16 CO CONC2023/0015485A patent/CO2023015485A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liang et al. | Development and delivery systems of mRNA vaccines | |
| JP7600208B2 (ja) | 拘束された脂質を含むナノ材料およびその使用 | |
| Sasso et al. | The progress and promise of RNA medicine—an arsenal of targeted treatments | |
| JP2022501412A5 (cg-RX-API-DMAC7.html) | ||
| JP2022530043A5 (cg-RX-API-DMAC7.html) | ||
| JP2020500539A5 (cg-RX-API-DMAC7.html) | ||
| TWI924663B (zh) | 用於抑制PNPLA3表現之RNAi劑、其醫藥組成物及使用方法 | |
| JP6280120B2 (ja) | 干渉rnaの内在性メカニズムを調節することができる核酸配列を送達するための製剤 | |
| Qin et al. | Development of spherical nucleic acids for prostate cancer immunotherapy | |
| JPH04505752A (ja) | オリゴヌクレオチドを使用する癌治療用の方法及び組成物 | |
| JP2002501511A (ja) | 脂質小胞への荷電した治療剤の高率封入 | |
| US11220686B2 (en) | Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules | |
| HUE025782T2 (en) | 5-Aza-cytosine-containing oligonucleotide analogs | |
| JP2013511964A (ja) | miRNA−100を含む医薬組成物ならびに血管増殖および内皮炎症を調節するためのその使用 | |
| FR2998899A1 (fr) | Methode de criblage a haut-debit pour l'identification de biomarqueurs, cibles therapeutiques ou d'agents therapeutiques | |
| TW202425952A (zh) | 脂質奈米顆粒藥物綴合物 | |
| Mao et al. | Optimized lipid nanoparticles enable effective CRISPR/Cas9-mediated gene editing in dendritic cells for enhanced immunotherapy | |
| Kim et al. | Strategy to Enhance Dendritic Cell‐Mediated DNA Vaccination in the Lung | |
| TW202120104A (zh) | 用於治療apoc3相關疾病及病症之方法 | |
| Abbasi Dezfouli et al. | Delivery Aspects for Implementing siRNA Therapeutics for Blood Diseases | |
| JP2023502182A5 (cg-RX-API-DMAC7.html) | ||
| EP1771548B1 (fr) | Utilisation de dendrimeres pour stimuler la croissance cellulaire | |
| EP1409672A2 (fr) | Oligonucleotides antisens capables d'inhiber la formation des tubes capillaires | |
| JPH08151333A (ja) | 脳腫瘍治療用ハイブリッド型リポソーム製剤 | |
| US20250195429A1 (en) | Lipid nanoparticles for delivering nucleic acid to peripheral blood mononuclear cells, and method for delivering nucleic acid to peripheral blood mononuclear cells using same |